Skip to content
City PM
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
Monday 16 November 2020 1:15 pm

Cineworld shares soar on Moderna coronavirus vaccine breakthrough

By: Jessica Clark

Add as a preferred source on Google
cineworld moderna coronavirus vaccine
Cineworld has closed all of its venues in the UK and Ireland as film studios have delayed major releases during the coronavirus pandemic

Cineworld’s share price soared this morning following a second coronavirus vaccine breakthrough on hopes that an end to the pandemic could save the struggling entertainment firm. 

The cinema chain’s stock rose as much as 21 per cent after US biotechnology company Moderna announced that early data suggested that its Covid-19 vaccine is 94.5 per cent effective.

Cineworld’s share price is up 16.74 per cent at 51.8p following the initial surge. 

The London-listed company last month closed all of its 128 theatres in the UK and Ireland after movie studios delayed big budget releases, such as the latest James Bond firm No Time to Die. 

It did not set out a timeline for reopening, but said it would “continue to monitor the situation closely and will communicate any future plans to resume operations once film studios are able to bring their pipeline of major movie releases back to the big screen”. 

In September Cineworld posted revenue of $712.4m in the six months to the end of June, down 67 per cent on last year.

It swung to a pre-tax loss of $1.6bn, compared to a $139.7m profit in 2019 following the forced closure of all of its venues during coronavirus lockdowns around the world. 

The beleaguered company’s shares rallied last week after US pharmaceuticals giant Pfizer announced that its vaccine is 90 per cent effective in preventing Covid-19. 

The roll-out of a working vaccine would allow cinemas to resume operations.

The UK government does not currently have a deal with Moderna to purchase doses as it did with Pfizer, but is in negotiations.

Read more

AAHI’s SLA-SE Adjuvant Technology Powers Lilly’s Acquisition of Curevo’s Next-Generation Shingles Vaccine

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business
  • Retail

Related Topics

  • Cineworld Group

Trending Articles

  • Top Burnham adviser calls for capital gains and inheritance tax hikes

  • Housebuilding giants hit with £4.5bn lawsuit for allegedly overcharging buyers

  • A meeting with the breakfast king of Mayfair

  • As it happened: Stocks jump on defence and metals boost; Oil on track to shed a fifth on US-Iran peace hopes

  • BT tops FTSE 100 after finding new home for international business with Verizon joint venture

More from City PM

  • AAHI’s SLA-SE Adjuvant Technology Powers Lilly’s Acquisition of Curevo’s Next-Generation Shingles Vaccine

    Business Wire
  • Expensify Named Expense Management Platform of the Year

    Business Wire
  • Quantum could be Britain’s next tech breakthrough

    Opinion
    Advanced quantum computer with intricate circuits and glowing interface, illustrating cutting-edge technology innovations
  • How Britain’s most resilient founders turn failures into fuel

    Business
    Dougal Shaw, Steph Hind, Gurinder Dhillon, and John Stapleton speaking on stage at SCALE 2 business event
  • Treasury still has £5bn to spend on Covid-19 – taking total bill to £385bn

    Economics
    The UK economy has seen low growth under Chancellor Rachel Reeves.
  • IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine

    Business Wire
  • Award winning Medtech firm excels again

    Partner
    Unable to generate alt text without specific article content or context. Please provide more details or context.
  • Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026

    Business Wire

City PM — European politics, business and analysis.

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Topics

  • Business
  • Markets
  • AI
  • Technology
  • Opinion
  • Energy

More

  • Politics
  • Economics
  • Fintech
  • Legal
  • Sport
  • Life

Company

  • About City PM
  • Editorial Policy
  • Corrections
  • Contact
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 City PM · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
About · Editorial Policy · Corrections · Contact · Privacy